Next Article in Journal
The Emerging Role of the Microenvironment in Endometrial Cancer
Next Article in Special Issue
Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles
Previous Article in Journal
Cancer Associated Fibroblasts: Naughty Neighbors That Drive Ovarian Cancer Progression
Previous Article in Special Issue
Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis
 
 
Article

The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients

1
Medizinisches Labor Pachmann, SIMFO GmbH, Kurpromenade 2, 95448 Bayreuth, Germany
2
SIMFO GmbH, Kurpromenade 2, 95448 Bayreuth, Germany
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(11), 407; https://doi.org/10.3390/cancers10110407
Received: 9 October 2018 / Accepted: 26 October 2018 / Published: 29 October 2018
(This article belongs to the Special Issue Circulating Tumor Cells (CTCs))
After five years of endocrine therapy, patients with ER+ (estrogen receptor positive) breast cancer face the question of the benefit of further treatment. Ten years of endocrine therapy has been demonstrated to improve survival compared to five years. However, the individual benefit of continuation remains unclear. Therefore, markers for predicting benefit from endocrine treatment and extended endocrine treatment are desperately needed. In this study the dynamics over time of the tumor cells circulating in peripheral blood of patients, circulating tumor cells/ circulating epithelial tumor cells (CTC/CETC), as the systemic part of the tumor were investigated in 36 patients with ER+ primary breast cancer. CTC/CETCs were monitored serially during and after endocrine therapy. After termination of endocrine therapy 12 patients showed an increase in CTC/CETCs, with 8 of 12 suffering relapse. No change or a reduction was observed in 24 patients, with 2 of 24 suffering relapse. Initial tumor size was marginally prognostic (p = 0.053) but not nodal status nor the mere number of CTC/CETCs. Only the trajectory of CTC/CETCs was a statistically significant predictor of relapse free survival (increasing cell numbers: mean = 940 days vs. stable/decreasing cell numbers mean not reached). Individual cases demonstrated that an increase of CTC/CETCs after discontinuation of tamoxifen therapy could be stopped by resuming the endocrine therapy. View Full-Text
Keywords: breast cancer; circulating tumor cells; endocrine therapy; longtime surveillance breast cancer; circulating tumor cells; endocrine therapy; longtime surveillance
Show Figures

Figure 1

MDPI and ACS Style

Pachmann, K.; Schuster, S. The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients. Cancers 2018, 10, 407. https://doi.org/10.3390/cancers10110407

AMA Style

Pachmann K, Schuster S. The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients. Cancers. 2018; 10(11):407. https://doi.org/10.3390/cancers10110407

Chicago/Turabian Style

Pachmann, Katharina, and Stefan Schuster. 2018. "The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients" Cancers 10, no. 11: 407. https://doi.org/10.3390/cancers10110407

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop